Related Experiment Videos
Inflammatory cells in ischemic acute renal failure
John J Friedewald1, Hamid Rabb
1Renal Divisions, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Kidney International
|July 16, 2004
Summary
Inflammatory pathways, including T cells and B cells, play a key role in ischemic acute renal failure (ARF). Modulating these immune cells offers potential for treating ARF.
Area of Science:
- Nephrology
- Immunology
- Pathophysiology
Background:
- Ischemic acute renal failure (ARF) involves complex mechanisms with acute and chronic effects.
- Emerging research highlights inflammatory pathways and microvascular events in ARF pathogenesis.
- Initial renal ischemia/reperfusion (I/R) injury involves microvascular changes and leukocyte-endothelial interactions.
Purpose of the Study:
- To explore the role of various immune cells in mediating renal ischemia/reperfusion (I/R) injury.
- To investigate the contribution of T cells, B cells, and macrophages in ARF.
- To understand the involvement of resident kidney cells in I/R damage and repair.
Main Methods:
- Review of experimental models of renal ischemia/reperfusion (I/R) injury.
- Analysis of the roles of neutrophils, T cells (CD4+), B cells, and macrophages.
- Examination of the impact of leukocyte-endothelial interactions and interferon-gamma (IFN-gamma).
Main Results:
- Blocking leukocyte-endothelial interactions shows protective effects in experimental ARF models.
- Neutrophils have a modest, but T cells (particularly CD4+ T cells) directly mediate renal injury.
- B cells are implicated in ARF, while the role of macrophages remains largely unknown.
Conclusions:
- CD4+ T cells, via IFN-gamma and costimulatory molecules, are significant modulators of ARF.
- Resident kidney cells likely contribute to inflammatory pathogenesis and repair, but their exact role requires further investigation.
- Targeting inflammatory cells, especially mononuclear leukocytes, presents a promising strategy for future ARF clinical trials.